Halozyme Therapeutics, Inc. (HALO) Max Pain Analysis

Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.

Halozyme Therapeutics, Inc. (HALO) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $8.31B, listed on NASDAQ, employing roughly 350 people, carrying a beta of 0.88 to the broader market. Halozyme Therapeutics, Inc. Led by Helen I. Torley, public since 2004-03-16.

Snapshot as of May 15, 2026.

Spot Price
$67.39
Max Pain Strike
$65.00
Total OI
17.6K

As of May 15, 2026, Halozyme Therapeutics, Inc. (HALO) max pain sits at $65.00, which is below the current spot price of $67.39 (3.5% away). Spot sits 3.5% below max pain - close enough that a routine end-of-cycle gamma roll could pull price toward the level, but far enough that catalyst-driven flow would dominate. HALO sits in the lower-price band (spot $67.39), where $0.50-$2.50 strike spacing makes pin-to-strike effects easy to spot but per-contract dollar gamma is smaller. Total open interest across the listed chain is comparatively thin (17.6K contracts), so single-strike pinning is less reliable than it is for high-OI names. HALO is currently in positive dealer gamma ($495.7K), the regime that mechanically reinforces pinning by inducing dealers to buy weakness and sell strength near heavy-OI strikes. Max pain identifies the strike at which the aggregate dollar value of all outstanding options contracts would expire with the least total intrinsic value, a gravitational reference rather than a price target.

HALO Strategy Implications at the Current Max Pain Level

With spot 3.5% from the $65.00 max-pain level and Halozyme Therapeutics, Inc. in a positive-gamma regime, where dealer hedging mechanically pulls spot toward heavy-OI strikes, strategy selection turns on cycle position and dealer positioning. Iron condors and credit spreads centered near the max-pain strike capture the typical end-of-cycle convergence when the regime supports pinning; ratio backspreads or directional debit structures fit names where catalyst flow is likely to overwhelm the hedging-driven pull. The gamma-exposure page shows the per-strike dealer book that determines whether hedging will reinforce or fight the pin.

Learn how max pain is reported and how to read the data →

HALO highest open-interest contracts

TypeStrikeExpirationVolumeOIIVBidAsk
PUT$65.00Sep 18, 202630311436.9%$4.20$4.80

Top 1 contracts from the ORATS-sourced nightly scan; ranked by oi within the broader S&P 500/400/600 + ETF universe.

Frequently asked HALO max pain analysis questions

What is the current HALO max pain strike?
As of May 15, 2026, Halozyme Therapeutics, Inc. (HALO) max pain sits at $65.00, which is 3.5% below the current spot price of $67.39. Max pain identifies the strike at which aggregate option-buyer payouts at expiration are minimized; it is a gravitational reference, not a price target. A 3.5% gap is close enough that a routine end-of-cycle gamma roll could pull spot toward the level, but far enough that catalyst-driven flow typically dominates.
Does HALO pin to its max pain strike at expiration?
HALO is currently in positive dealer gamma, the regime that mechanically reinforces pinning. Dealers hedging long-gamma books buy weakness and sell strength near high-OI strikes, which pulls spot toward those levels into expiration. Total open interest across HALO (17.6K contracts) is one input to how plausible a clean pin is - heavier total OI concentrated at fewer strikes raises the probability; thin OI spread across many strikes lowers it. Pinning is strongest in heavily-traded names with large open-interest concentrations at high-OI strikes during the final week of an OPEX cycle. Whether HALO actually pins on a given expiration depends on the OI distribution, the dealer-gamma sign, and the absence of catalyst-driven moves that overwhelm hedging-driven flow.
How is HALO max pain calculated?
Max pain is computed by summing the dollar value of all in-the-money options at each candidate settlement strike across listed expirations, then selecting the strike that minimizes total intrinsic-value payout to option buyers. The calculation uses the full open-interest distribution and weighs both calls and puts. HALO put/call OI ratio is 0.38 - call-heavy, which biases the max-pain calculation toward strikes above current spot when the call OI concentrates there.